Rachel N. Grisham, MD, discusses the mechanism of action of VS-6766 in patients with recurrent low-grade serous ovarian cancer.
Rachel N. Grisham, MD, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of VS-6766 (formerly CH5126766) in patients with recurrent low-grade serous ovarian cancer.
VS-6766 is a dual RAF/MEK inhibitor that is currently under investigation in a phase 2 trial (NCT04625270) in combination with defactinib (GOG305), according to Grisham, who is a principal investigator of the trial in the United States. The agent is currently being developed for patients with low-grade serous ovarian cancer, a disease in which MEK inhibitors have recently demonstrated promising clinical activity.
As a dual RAF/MEK inhibitor, it may be possible to enhance the population of patients who can benefit from targeted therapies, as well as target a larger population of patients, Grisham concludes.